| Drug Name |
Vorinostat |
| Drug ID |
BADD_D02370 |
| Description |
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs. |
| Indications and Usage |
For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XH01 |
| DrugBank ID |
DB02546
|
| KEGG ID |
D06320
|
| MeSH ID |
D000077337
|
| PubChem ID |
5311
|
| TTD Drug ID |
D0E7PQ
|
| NDC Product Code |
0006-0568; 63285-009 |
| UNII |
58IFB293JI
|
| Synonyms |
Vorinostat | N1-Hydroxy-N8-phenyloctanediamide | N1 Hydroxy N8 phenyloctanediamide | NHNPODA | Suberoyl Anilide Hydroxamic Acid | Suberoylanilide Hydroxamic Acid | N-Hydroxy-N'-phenyloctanediamide | N Hydroxy N' phenyloctanediamide | Suberanilohydroxamic Acid | M344 | MK-0683 | MK 0683 | MK0683 | 18F-SAHA | 18F-Suberoylanilide Hydroxamic Acid | 18F Suberoylanilide Hydroxamic Acid | Zolinza |
